激素抵抗型前列腺癌分子靶向治疗的进展

Targeted therapies for hormone-refractory prostate cancer

前列腺癌是中老年男性最常见的恶性肿瘤之一,初期内分泌治疗有效,但几乎都会转变为激素抵抗型前列腺癌(hormone-refractory prostate cancer,HRPC)。多西紫杉醇联合强的松是HRPC标准的一线治疗,但目前尚无公认的二线治疗方案,本文拟着眼于HRPC形成的分子机制,介绍以肿瘤新生血管、细胞信号传导通路、凋亡、增殖及免疫调节为靶点治疗方法的最新进展。

Prostate cancer is one of the most common type of cancer among men after middle age.Androgen withdrawal can delay its progression in the initial stage,but it finally becomes independent of androgens in almost all the cases.The combination of docetaxel with prednisone is currently a standard first-line treatment for patients with hormone-refractory prostate cancer（HRPC）,but hitherto there is no established second-line therapy.In view of the molecular pathogenesis of HRPC,this article presents an overview on several promising drugs that target specific pathways,involving angiogenesis,cell signaling,apoptosis and proliferation,and immune modulation,either as single agents or in combination with cytotoxic chemotherapy.